Multi-omics and experimental validation identify RAPGEF2 as a protective prognostic biomarker in clear cell renal cell carcinoma

Abstract

Highlights • Single-cell, spatial transcriptomic and multi-omics analyses reveal endothelial-enriched RAPGEF2 in KIRC.• RAPGEF2 independently predicts favorable survival across multicenter KIRC cohorts.• Experimental validation links RAPGEF2 to tumor suppression and immunotherapy benefit.